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Summary 
The  tumor  necrosis  factor  (TNF)  c~  gene  lies  within  the  class  III  region  of  the  major 
histocompatibility complex (MHC), telomeric to the class II and centromeric to the class I region. 
We have recently described the first polymorphism within  the human  TNF-ct locus.  This is 
biallelic and lies within the promoter region. Frequency analysis  of the TNF-o~ polymorphism, 
using the polymerase chain reaction and single-stranded conformational polymorphism, in HLA- 
typed individuals, reveals a very strong association between the uncommon TNF allele and HLA 
A1, B8, and DR3 alleles.  This is the first association between TNF-ct and other MHC alleles 
and raises the possibility that the uncommon TNF-ct allele may contribute to the many autoimmune 
associations of the A1,B8,DR3  haplotype. 
T 
he genes for TNF-c~ and -B lie within  a 7-kb stretch 
of DNA in the class III region of the MHC (1, 2). The 
TNF locus lies 250 kb centromeric of HLA B and 350 kb 
telomeric of the class III cluster (3, 4). TNF-o~ is a central 
mediator  of the inflammatory response and has important 
immunological activities (5). Because of these features, there 
has been much speculation that variations within the TNF 
locus may contribute to the etiology of MHC-related autoim- 
mune diseases. 
Regulation of TNF production occurs at the transcriptional 
and posttranscriptional  levels  (6,  7).  Sequences within  the 
5' DNA control the rate of transcription (8, 9). We have re- 
cently described a biallelic polymorphism in this region of 
the TNF-ct locus that  involves the substitution of guanine 
by adenosine in the uncommon  (TNF2)  allele  (10). 
Using the PCR and single-stranded conformational anal- 
ysis, we have tested the frequency of the TNF alleles in HLA- 
typed normal individuals from a north European population. 
We have found the TNF2 allele to be very strongly associated 
with HLA A1, BS, and DR3 alleles.  This raises  the possi- 
bility that A1,B8,DR3 haplotypic associations with autoim- 
mune diseases may also be related to polymorphism within 
the TNF-ct locus. 
Materials and Methods 
DNA  Preparation,  DNA  was  isolated  from  anticoagulated 
PBMC by standard methods (11). 
HLA Typing.  HLA-A and -B antigens were typed using stan- 
dard National Institutes of Health microlymphocytotoxicity assays. 
DR typing was performed as follows: 49 samples were typed 
by standard microcytotoxicity  tests using antisera to each of the 
alleles DR1, -2, -3, -4, -5, -w6, -7, -w8, -9, and -wl0. Frozen lym- 
phocytes were thawed and incubated overnight at room tempera- 
ture in RPMI with 20% FCS before separation into B and T cells. 
Weak results were confirmed by RFLP analysis. The remaining 
118 samples were typed for DRB1 by PCR amplification of DR.B1 
exon 2 (sense  primer 5'-CCGGTCGACTGTCCCCCCAGCACGT- 
TTC-3';  antisense primer 5'-GAATTCTCGCCGCTGCACTGTG- 
AAGC-3').  PCR products  were analyzed by dot blot hybridiza- 
tion with DRB1 sequence-specific  oligonucleotide probes (12, 13). 
PCR Amplification of TNF-cr.  For sequencing of the TNF-c~ 
5' DNA and exon 1, 985 bp of DNA was amplified by PCR using 
a 5' primer (5-TCCCCAGGCTTGTCCCTGCTACC-3)  and a 3' 
biotinylated primer (5-GATGAAGCTIGGCCAGGCACTCAC-3). 
For further screening by single-stranded conformational polymor- 
phism  (SSCP), 107 bp of DNA was amplified using a 5' primer 
(5-AGGCAATAGGTTTTGAGGGCCAT-3) and (5-TCCTCCCT- 
GCTCCGATTCCG-3)  as the 3' primer. 100 ng of genomic DNA 
was used for amplification with 0.2 #M concentrations  of each 
primer in a total volume of 50 #1 containing Taq DNA polymerase 
1.25 U  (Northumbria Biologicals Ltd.,  Northumberland,  UK), 
200 #M of each dNTP (Boehringer Mannheim,  Mannheim,  Ger- 
many), and PCR reaction buffer at a final concentration of 10 mM 
Tris-HC1, 1.5 mM MgC12, 50 mM KC1, and 0.1% Triton X-100 
(Northumbria Biologicals Ltd.).  Cycling was performed at 94~ 
for 3 min, 60~  for 1 min, and 72~  for 1 min, followed by 35 
cycles of 94~  for 1 min, 60~  for 1 min,  and 72~  for 1 min, 
with a final cycle of 94~  for 1 min, 60~  for 1 min,  and 72~ 
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with ethidium bromide, and visualized with UV light. Negative 
controls, using water instead of template, were performed in each 
experiment. 
DNA Sequence  Analysis.  PCR products were purified  using the 
Geneclean II kit (Stratech Scientific,  Luton, UK). Single-stranded 
DNA template was prepared using streptavidin-coated magnetic 
beads (Dynal, Liverpool, UK). To 50/~1 purified PCR product was 
added 50/zl of dynabeads and 50 #1 solution A, containing 0.17% 
TritonoX, 100 mM NaC1, 10 mM Tris/HC1, and I mM EDTA (all 
supplied by Sigma Immunochemicals, Dorset, UK). These were 
mixed and shaken mechanically for 30 min at room temperature. 
The PCR product/streptavidin-coated beads complex was washed 
with 100/zl solution A, and then resuspended in 32/xl 10 mM 
Tris/1 mM EDTA (TE) and 8/zl of 1 M NaOH/4 mM EDTA so- 
lution (Sigma Immunochemicals). This was left at room tempera- 
ture for 5 min. The PCR productAtreptavidin-coated beads com- 
plex was then precipitated using a magnet, and the supernatant 
containing the nonbiotinylated strand removed. The beads were 
again resuspended in 32/zl TE and 8 #1 of I M NaOH/4 mM 
EDTA solution, and the process was repeated. After this, the com- 
plex was again washed with 100/~1 solution A and resuspended 
in 7/~1 water. Sequencing was performed by the dideoxy chain ter- 
mination method using a Sequenase  Version 2 kit (US Biochemical 
Corp.,  Cleveland, OH). 
SSCP Analysis.  50/xl PCR product was denatured with 2.5 
#1 1 M NaOH and heated to 42~  for 5 min. 6/~1 100% forma- 
mide was then added. The samples  were loaded on a 9% polyacryl- 
amide gel and electrophoresed for 16 h at 4 V/cm and 4~  The 
DNA was stained with ethidium bromide and visualized under 
UV light. 
Southern Blot Analysis.  DNA was transferred  from an ethidium 
bromide-stained  9% polyacrylamide  gel to a nylon membrane (Zeta- 
Probe; Bio-Rad  Laboratories,  Hercules, CA) by electroblotting  (40C, 
0.2 A for 12 h). After denaturation and fixation by treatment with 
0.4  M  NaOH,  hybridization with a 3,-32P-end labeled TNF-c~ 
oligonucleotide (  5  -TTCTGGGCCACTGACTGATTTGTG-3, 
matching positions 3817 to 3840 of the published sequence [1]) 
was obtained by standard protocols (14). 
High stringency washes were performed at 65~  2x  SSC for 
15 min, followed by 2x  SSC for 15 rain, 2x  SSC/0.1% SDS for 
30 min, and finally  0.1x  SSC for 10 min. The membrane was left 
to dry at room temperature for 10 min. Visualization of the hy- 
bridized probe was by autoradiography (Hyperfilm B-max; 2 x 
X.OMAT  intensifying  screens [Genetic Research Ltd.,  Essex, 
UK] 6 h exposure). 
StatisticalAnalysis.  A 2 x 2 table was constructed for each DR 
allele and the corresponding TNF allelic frequencies and the X 2 
value was calculated using Yates' correction or, when appropriate, 
Fisher's exact test was used to determine statistical significance. 
Figure 1.  TNF-~  polymorphism.  (a) G homozygote  at position -308 
(TNF1 allde); (b) G/A heterozygote  at position  -308 (TNF1/TNF2  alleles). 
internal end-labeled oligonudeotide confirmed the identity 
of the polymorphic bands (Fig.  2 B). 
The TNF2 allele is strongly associated with HLA A1 (Table 
1), B8 (Table 2), and DR3 (Table 3) positivity. The associa- 
tion was even stronger when the three alleles were analyzed 
together (Table 4).  The lower degree of association of A1 
compared with B8 is most probably due to the greater phys- 
ical distance from the TNF-c~ locus.  TNF1 is significantly 
associated  with HLA DR4  and DR6  alleles. 
In view of the close physical proximity of the TNF locus 
to these genes, the above associations are almost certainly due 
Results and Discussion 
A biallelic polymorphism at position  -308 was observed 
involving the substitution of guanine by adenosine in the 
TNF2 allele (Fig.  1). This is not a highly conserved region 
between mouse, rabbit, and humans, and does not lie within 
a currently recognized DNA-binding protein sequence motif. 
Using SSCP, 167 normal individuals were screened for the 
TNF-cx polymorphism. Bands corresponding to the two al- 
leles were dearly visible after partial denaturation of the PCR 
product (Fig.  2 A). Southern analysis of the SSCP with an 
Figure 2.  (a) SSCP  analysis  of  position  -308. Lanes:  I, PhiX174/HaellI 
ladder; 2,  negative control; 3,  homozygote  TNF1; 4,  heterozygote 
TNF1/TNF2; 5, homozygote  TNF2. (b) Southern  probing  of  SSCP with 
TNF-cx probe. Lanes 1, PhiX174/HaeIII  ladder; 2, homozygote  TNF1; 
3, heterozygote  TNF1/TNF2;  4, homozygote  TNF2; and 5, negative  con- 
trol. The bands  corresponding  to the two TNF andes  and double-stranded 
DNA are indicated. (o) Two nonspecific,  but constant, bands. 
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DR allele  TNF1  TNF2  p  OR* 
DR1  9  0  NS 
DR2  40  12  NS 
DtL3  6  37  p <10-10 
DR4  53  8  p <10 -3 
DR5  19  10  NS 
DR6  44  8  p <10 -2 
DR7  27  10  NS 
DR8  9  2  NS 
DR9  3  2  NS 
DR10  2  0  NS 
22 
-4 
-3 
* Odds ratio. 
n =  161. 
Table  2.  Association of HLA AI  Allele with TNF2 
TNF2-  TNF2 + 
A1 +  18  28 
A1-  69  12 
n ~  127; p <10-6; OK =  8.9. 
to linkage disequilibrium. Previously described polymorphisms 
at the TNF locus have all involved the TNF-/J gene (15, 16), 
or have been in the corresponding upstream DNA (17, 18). 
The polymorphism that we describe here lies within the 
region of the TNF-ot gene believed to be important in regu- 
lation of transcription. Recent reports have demonstrated that 
a single base polymorphism within a promoter region may 
alter both the rate of gene transcription and the rate of pro- 
tein production (19). This can occur even when the poly- 
morphism does not alter the binding of tram-activating factors 
at the altered base position and may be related to changes 
in the secondary structure of DNA that affect access of tran- 
scription factors (20). 
Stable interindividual production rates for TNF-oe have been 
demonstrated (21), and in addition, production rate has been 
shown to correlate with DR alleles. DR2-positive individ- 
uals produce low levels, whereas DR3-  and DR4-positive 
Table  3.  Association of HLA B8 Allele with TNF2 
TNF2-  TNF2 + 
B8 +  8  25 
B8-  82  12 
n  m  127;/7  <10-10;  OR  z  21.3. 
Table  4.  Association of HLA A1,B8,DR3 with TNF2 
TNF2-  TNF2 + 
A1 B8 DR3 +  1  20 
A1 B8 DR3-  95  24 
n  m  140; p  <10-10;  OR  z  79. 
individuals produce high levels of TNF-c~ (22).  The major 
control of TNF-c~ production seems to be at the posttran- 
scriptional level (23).  Untranslated sequences in the fourth 
exon are central to the control of translational efficiency (24), 
and it will be interesting to see if genetic variation in this 
region may also contribute to the phenotypic associations with 
DR alleles. 
The association of autoimmune diseases with different DR 
alleles has been widely recognized for some time. HLA haplo- 
types that include DR3  (especially  HLA A1,B8,DR3)  are 
known to be associated with a wide range of autoimmune 
diseases including insulin-dependent diabetes  mellitus, sys- 
temic lupus erythematosus, Graves'  disease, and celiac dis- 
ease (25).  A previous report has implicated the TNF locus 
on DR3 haplotypes in diabetes  (26).  Whether this associa- 
tion is due to the products of these alleles directly or to genes 
in linkage disequilibrium with them, is not clear. If the TNF2 
allele can be shown to have a higher relative risk than class 
I and II alleles in these diseases, then the case for the involve- 
ment of TNF-ot as a genetic predisposition factor will be 
strengthened. 
TNF-ot has been implicated as a pathogenic mediator in 
many inflammatory, infectious, and immune diseases (27). 
The present report is the first to link allelic polymorphism 
in TNF-oe to the MHC class I and class II regions. In view 
of this, it is interesting to speculate that TNF-ot might con- 
tribute causally to the many autoimmune diseases associated 
with the HLA A1,B8,DR3  haplotype. 
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